Delivery Order SPE2DB20D1109-SPE2DB25FP61D
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,279.00 to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of VIMPAT 10 mg/mL solution in 200mL quantities. This is a firm fixed price, non-set-aside contract with a completion date of June 6, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,409.40 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in a 200 ml volume. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, completed on September 10, 2025, with an ultimate completion date of September 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 28, 2025, for the supply of VIMPAT 10 mg/ml solution in a 200 ml quantity, valued at $1,964.65. This firm fixed-price delivery order, which is set to be completed by May 29, 2025, represents a pediatric or adjunctive treatment pharmaceutical for seizure management. The contract was competitively awarded with no set-aside designation and will be fulfilled from AmerisourceBergen Drug Corp's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 100 mg tablets (60-count units) valued at $2,048.51. This firm fixed-price delivery order, which is expected to be completed by August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.32 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200ml quantities. This non-competitive delivery order, issued on August 14, 2025, represents a firm fixed-price procurement executed under a child contract arrangement with an ultimate completion date of August 15, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,959.86. This competitively awarded, firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation and will...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200 ml quantities, with a ceiling value of $1,048.32. This is a firm fixed-price delivery order with an ultimate completion date of September 4, 2025, awarded on September 3, 2025. The award carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- AmerisourceBergen Drug Corp was awarded a delivery order on October 14, 2025, by the Defense Logistics Agency for VIMPAT 200 mg tablets (60-count units) with a ceiling value of $1,180.74. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 15, 2025. The award represents a continuation of pharmaceutical supply services to support federal medical procurement needs, with performance taking place at the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of VIMPAT 200 mg/20 ml vials valued at $1,365.00. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,310.40 for VIMPAT 10 mg/mL Solution in a 200 mL quantity, with an ultimate completion date of August 20, 2025. This is a firm fixed price, non-set-aside contract awarded on August 19, 2025, with performance to be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. VIMPAT (lacosamide) is an antiepileptic medication used in the treatment of seizure disorders. This delivery order is...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP61DDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 20, 2025, for VIMPAT 10 mg/mL solution in 200 mL quantities, with a ceiling value of $1,524.74. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 21, 2025. The contract is unset-aside and represents a child order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order falls under AmerisourceBergen's prime Indefinite Delivery Vehicle (SPE2DX) with the Defense Logistics Agency, valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military healthcare programs worldwide. The IDV enables the company to supply a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. VIMPAT, an antiepileptic medication, is consistent with AmerisourceBergen's extensive portfolio of neurological and specialized pharmaceutical treatments delivered through the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/20/25 |